DK1137439T4 - Stabilisering af rapamyciner eller rapamycinderivater - Google Patents

Stabilisering af rapamyciner eller rapamycinderivater

Info

Publication number
DK1137439T4
DK1137439T4 DK99959381.7T DK99959381T DK1137439T4 DK 1137439 T4 DK1137439 T4 DK 1137439T4 DK 99959381 T DK99959381 T DK 99959381T DK 1137439 T4 DK1137439 T4 DK 1137439T4
Authority
DK
Denmark
Prior art keywords
rapamycins
stabilization
rapamycin derivatives
rapamycin
derivatives
Prior art date
Application number
DK99959381.7T
Other languages
Danish (da)
English (en)
Other versions
DK1137439T3 (da
Inventor
Samuel Petit
Guy Stone
Franacois Navarro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1137439(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of DK1137439T3 publication Critical patent/DK1137439T3/da
Application granted granted Critical
Publication of DK1137439T4 publication Critical patent/DK1137439T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
DK99959381.7T 1998-12-07 1999-12-06 Stabilisering af rapamyciner eller rapamycinderivater DK1137439T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds
PCT/EP1999/009521 WO2000033878A2 (en) 1998-12-07 1999-12-06 Stabilization of macrolides

Publications (2)

Publication Number Publication Date
DK1137439T3 DK1137439T3 (da) 2007-09-10
DK1137439T4 true DK1137439T4 (da) 2012-03-19

Family

ID=26314797

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99959381.7T DK1137439T4 (da) 1998-12-07 1999-12-06 Stabilisering af rapamyciner eller rapamycinderivater

Country Status (38)

Country Link
US (5) US6605613B2 (https=)
EP (4) EP2279751A3 (https=)
JP (3) JP3805625B2 (https=)
KR (2) KR100695834B1 (https=)
CN (2) CN1261163C (https=)
AR (3) AR026102A1 (https=)
AT (1) ATE365051T1 (https=)
AU (1) AU759219B2 (https=)
BE (1) BE1012869A3 (https=)
BR (1) BR9915986A (https=)
CA (3) CA2351580C (https=)
CO (1) CO4980847A1 (https=)
CY (1) CY1106870T1 (https=)
CZ (2) CZ303006B6 (https=)
DE (1) DE69936352T3 (https=)
DK (1) DK1137439T4 (https=)
ES (1) ES2288033T5 (https=)
FR (1) FR2786771B1 (https=)
GB (2) GB9826882D0 (https=)
HK (1) HK1038889B (https=)
HU (2) HU228939B1 (https=)
ID (1) ID29250A (https=)
IL (1) IL143092A0 (https=)
IT (1) IT1319701B1 (https=)
MY (2) MY127579A (https=)
NO (2) NO332698B1 (https=)
NZ (2) NZ511936A (https=)
PE (1) PE20001333A1 (https=)
PL (2) PL208854B1 (https=)
PT (1) PT1137439E (https=)
RU (1) RU2243769C2 (https=)
SG (1) SG151072A1 (https=)
SI (1) SI1137439T2 (https=)
SK (2) SK286688B6 (https=)
TR (2) TR200101416T2 (https=)
TW (2) TWI270550B (https=)
WO (1) WO2000033878A2 (https=)
ZA (1) ZA200104360B (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
MXPA04007847A (es) 2002-02-13 2005-02-24 Biogal Gyogyszergyar Metodo para extraer un macrolido de biomateria.
NZ537829A (en) 2002-07-30 2006-09-29 Wyeth Corp Parenteral formulations containing a rapamycin hydroxyester
TR200500302T3 (tr) * 2003-03-31 2005-04-21 Biogal Gyogyszergyar Rt. Makrolidlerin kristalizasyonu ve saflaştırılması.
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
TW200523266A (en) 2003-07-24 2005-07-16 Biogal Gyogyszergyar Method of purifying macrolides
CA2539324A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
CN1889994A (zh) * 2003-12-10 2007-01-03 艾克若克斯Dds有限公司 伴随透皮或局部药物输送的不希望的效果的治疗方法
US8551512B2 (en) 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
US20060094744A1 (en) * 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
JP4974903B2 (ja) 2005-02-09 2012-07-11 参天製薬株式会社 疾患または状態を処置するための液体処方物
BRPI0619592A2 (pt) * 2005-12-07 2016-09-06 Wyeth Corp métodos para medir a qualidade da partícula de um composto de rapamicina, para determinar o tamanho de partícula médio de uma amostra e a cristalinidade de um composto de rapamicina, e para a purificação de rapamicina
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
RU2008121713A (ru) * 2005-12-20 2010-01-27 Вайет (Us) Контроль стабильности лекарственной формы cci-779 посредством контроля примесей лекарственныхого вещества
WO2007092620A2 (en) * 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
PL2001466T3 (pl) 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
WO2011151704A2 (en) 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
WO2011156025A1 (en) * 2010-06-07 2011-12-15 Telik, Inc. Crystalline Ezatiostat Hydrochloride Ansolvate
EP2601201B1 (en) * 2010-08-04 2014-09-24 Meril Life Sciences Pvt. Ltd. Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties"
WO2012066502A1 (en) 2010-11-19 2012-05-24 Biocon Limited Processes for preparation of everolimus and intermediates thereof
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (https=) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
US10383860B2 (en) 2015-07-28 2019-08-20 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof, and method for producing the same
JP6793651B2 (ja) * 2015-08-28 2020-12-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017047618A1 (ja) * 2015-09-18 2017-03-23 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
JP6855470B2 (ja) 2016-05-27 2021-04-07 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
CN119431400A (zh) * 2020-03-27 2025-02-14 波士顿科学国际有限公司 用于使药物结晶的方法
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
CA1338150C (en) † 1988-02-18 1996-03-12 Edward George Howard, Jr. Ceramic/distillable binder compositions
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
FI97472C (fi) 1991-05-07 1996-12-27 American Home Prod Menetelmä terapeuttisesti käyttökelpoisten rapamysiinijohdannaisten valmistamiseksi anti-inflammatorisina ja antifungaalisina aineina
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
EP1266900A1 (en) 1992-10-13 2002-12-18 Wyeth Carbamates of rapamycin
RU2181054C2 (ru) * 1994-11-02 2002-04-10 Новартис Аг Микроэмульсионный предконцентрат
EP0833828B1 (en) 1995-06-09 2002-11-20 Novartis AG Rapamycin derivatives
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
EP1208847B8 (en) * 1996-07-30 2007-02-14 Novartis AG Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
WO1998033482A1 (en) 1997-02-04 1998-08-06 Abbott Laboratories Pain reducing parenteral liposome formulation

Also Published As

Publication number Publication date
ITMI992520A1 (it) 2001-06-02
BE1012869A3 (fr) 2001-04-03
ES2288033T3 (es) 2007-12-16
US7572804B2 (en) 2009-08-11
SI1137439T2 (sl) 2012-05-31
GB9904934D0 (en) 1999-04-28
ITMI992520A0 (it) 1999-12-02
AU1657300A (en) 2000-06-26
JP2006111637A (ja) 2006-04-27
HUP0104489A3 (en) 2004-05-28
FR2786771A1 (fr) 2000-06-09
PE20001333A1 (es) 2000-12-12
PT1137439E (pt) 2007-09-25
CZ303006B6 (cs) 2012-02-22
NO20012424D0 (no) 2001-05-16
WO2000033878A3 (en) 2000-11-02
WO2000033878A2 (en) 2000-06-15
CA2732620A1 (en) 2000-06-15
IL143092A0 (en) 2002-04-21
US7741338B2 (en) 2010-06-22
FR2786771B1 (fr) 2002-12-27
AR048073A2 (es) 2006-03-29
EP2269651A2 (en) 2011-01-05
RU2243769C2 (ru) 2005-01-10
TR200101416T2 (tr) 2002-01-21
JP2002531527A (ja) 2002-09-24
NO20012424L (no) 2001-05-16
CZ20012001A3 (cs) 2001-09-12
ID29250A (id) 2001-08-16
NO20121113L (no) 2001-05-16
US20050107418A1 (en) 2005-05-19
CY1106870T1 (el) 2012-09-26
DK1137439T3 (da) 2007-09-10
US20030191148A1 (en) 2003-10-09
PL348333A1 (en) 2002-05-20
CN1876657B (zh) 2013-01-09
EP2279751A3 (en) 2011-02-16
US6605613B2 (en) 2003-08-12
CA2351580C (en) 2012-03-20
TWI270550B (en) 2007-01-11
US20090270441A1 (en) 2009-10-29
EP1743657A3 (en) 2007-03-28
US6852729B2 (en) 2005-02-08
GB9826882D0 (en) 1999-01-27
TW200540179A (en) 2005-12-16
JP3805625B2 (ja) 2006-08-02
SI1137439T1 (sl) 2008-06-30
US20080161334A1 (en) 2008-07-03
EP2279751A2 (en) 2011-02-02
BR9915986A (pt) 2001-09-04
EP1137439A2 (en) 2001-10-04
MY120594A (en) 2005-11-30
DE69936352T2 (de) 2008-02-14
ES2288033T5 (es) 2012-04-10
CO4980847A1 (es) 2000-11-27
PL196627B1 (pl) 2008-01-31
HK1038889A1 (en) 2002-04-04
US7297703B2 (en) 2007-11-20
ZA200104360B (en) 2002-01-16
CZ302210B6 (cs) 2010-12-22
EP1743657A2 (en) 2007-01-17
TWI248938B (en) 2006-02-11
HU228939B1 (en) 2013-07-29
EP1137439B1 (en) 2007-06-20
ATE365051T1 (de) 2007-07-15
TR200201428T2 (tr) 2002-12-23
AR026102A1 (es) 2003-01-29
NO334612B1 (no) 2014-04-22
HU230174B1 (hu) 2015-09-28
NZ527781A (en) 2004-11-26
KR20010101128A (ko) 2001-11-14
CA2351580A1 (en) 2000-06-15
JP5043308B2 (ja) 2012-10-10
HUP0104489A2 (hu) 2002-03-28
CN1876657A (zh) 2006-12-13
JP2005200429A (ja) 2005-07-28
CN1374872A (zh) 2002-10-16
SK286688B6 (sk) 2009-03-05
JP5165199B2 (ja) 2013-03-21
EP1137439B2 (en) 2011-11-23
CA2651609A1 (en) 2000-06-15
AR054444A2 (es) 2007-06-27
SK287325B6 (sk) 2010-07-07
SK7662001A3 (en) 2001-12-03
PL208854B1 (pl) 2011-06-30
MY127579A (en) 2006-12-29
KR100695834B1 (ko) 2007-03-19
DE69936352D1 (de) 2007-08-02
AU759219B2 (en) 2003-04-10
CN1261163C (zh) 2006-06-28
US20020032213A1 (en) 2002-03-14
NZ511936A (en) 2003-10-31
KR20060096477A (ko) 2006-09-11
SG151072A1 (en) 2009-06-29
CA2732620C (en) 2013-08-06
EP2269651A3 (en) 2011-03-09
DE69936352T3 (de) 2012-05-03
IT1319701B1 (it) 2003-10-27
HK1038889B (en) 2008-01-25
NO332698B1 (no) 2012-12-10

Similar Documents

Publication Publication Date Title
DK1137439T3 (da) Stabilisering af rapamyciner eller rapamycinderivater
DK1384478T3 (da) Antibiotiske sammensætninger indeholdende moxifloxacin til behandling af øjet
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1117669T3 (da) Antiviruspurinderivater
DK1032565T3 (da) Fremgangsmåde til fremstilling af derivater af taxoid-klassen
DK1386921T3 (da) Mellemprodukter til fremstilling af anti-trombotiske 4H-cycolopenta-1,3-dioxol-derivater
ID29021A (id) Komposisi galantamina pelepasan terkontrol
PT945132E (pt) Composicao de ibuprofeno
DK1438306T3 (da) Derivater af UK-2A
MA26766A1 (fr) Derives de phenylglycine
NO20010193D0 (no) Tiobenzimidazol-derivater
PT1073639E (pt) Derivados de quinolina
PT1095021E (pt) Derivados de quinolina
DK1077940T3 (da) 4-Phenylpiperidiner til behandling af pruritiske dermatoser
TR199900090A3 (tr) Benzosülfon türevleri
NO20010514D0 (no) Aminometylkarboksylsyre-derivater
ATE259810T1 (de) Phenyl-xanthinderivate
DK1107980T3 (da) Krystallinske former af EtO2C-CH2-(R)Cgl-Aze-Pab-OH
NO994790L (no) Estimering av permabilitet
DE69928262D1 (de) Substituierte chinazoline derivate
PT1056716E (pt) Derivados de ciclo-hexanodiolo
NO20011512D0 (no) 2-Fenylpyran-4-on derivater
DK1071330T3 (da) Stabilisering af isothiazolon
DK1134219T3 (da) Cucloalkylsubstituerede aminomethylpyrrolidinderivater
DE60012062D1 (de) Fluorierte Triazinderivate